RxDoctor Payments Data

John Hersey, OD

Optometrist · Winterport, MENPI 1700816352

Payments from drug & device makers

$286in general payments, 2019–2025

Across 10 payments — averaging $28.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$127
  • Coopervision Inc.$32
  • Bausch & Lomb Americas Inc.$32
  • Johnson & Johnson Vision Care, Inc.$23
  • AbbVie$21
  • Carl Zeiss Meditec AG$19
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$26693%
  • Gifts$197%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$286 in reported general payments places this provider in the 45th percentile of 224 optometrist providers in Maine.

See all optometrist providers in Maine

Medicare billing

Part B allowed, 2024
$55,517
Medicare patients
356
Services billed
651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Restasis MultidoseCyclosporine32$36,195
RestasisCyclosporine18$25,698
Latanoprost232$3,169
Timolol Maleate70$3,050
Prednisolone Acetate30$958
Tobramycin-DexamethasoneTobramycin/Dexamethasone32$887
Brimonidine Tartrate20$761
Ketorolac Tromethamine12$448
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha18$229
ErythromycinErythromycin Base17$204
Dorzolamide Hcl15$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis Multidose, Restasis$21$61,89350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 224 optometrist providers in Maine.

Other optometrist in Winterport

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →